Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology

Inclusion Criteria: * Patients age ≥18 years . * Patients present with chemotherapy-induced symptomatic anaemia. * Patients suffer from solid tumours, malignant lymphomas or multiple myeloma and have developed symptomatic anaemia due to their chemotherapy. * The patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle) * Patients eligible for epoetin alfa biosimilar treatment. Exclusion Criteria: * Patients are not receiving chemotherapy. * Patients already included in an epoetin zeta study. * Patients presenting with the contraindications to epoetin zeta. * Patients presenting with the hypersensitivity to the active substance or any of the excipients. * The patient presents erythroblastopenia, or 'pure red cell aplasia' (PRCA). * Patients with uncontrolled hypertension. * Patients who cannot receive adequate prophylaxis by antithrombotic agents.